论文信息 - Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results - 字舞流文

Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

R. Figlin | W. Miller | V. Master | M. Debenedette | J. Knox | S. Pal | R. Lance | A. Dudek | T. Logan | I. Tcherepanova | C. Nicolette | L. Karsh | A. Amin | D. Plessinger | W. L. Williams | Jeffrey M. Holzbeierlein